Clinical Trials Logo

Clinical Trial Summary

Open-label, dose escalation (Phase I) and dose expansion (Phase IIA) study of patients receiving intra-tumoral IMSA101 alone or in combination with an immune checkpoint inhibitor (ICI) (Phase I and II)


Clinical Trial Description

This is an open-label, dose escalation (Phase I), and dose expansion (Phase IIA) study designed to evaluate safety and efficacy of IMSA101 alone or in combination with an ICI (Phase I and II). Therefore, the study will be conducted in 2 phases. The dose of IMSA101 in Phase IIA will be based on the monotherapy and combination Recommended Phase 2 Doses (RP2Ds) from Phase I. The following methodology applies to all patients (unless otherwise indicated): - Pre-treatment screening radiographic tumor assessments will be collected within 30 days prior to initial dose for all patients. Photographic assessments for cutaneously-accessible lesions will be performed as detailed in a separate photography manual. - Treatment cycles will be 28 days in duration with lesions injected weekly on Day 1 for the first three weeks of Cycle 1 and then every 2 weeks during cycles 2 and beyond. - A single pre-defined lesion/lesion site (longest diameter ≥ 10 mm and ≤ 35 mm) shall be injected throughout study duration, if possible. Where the original injection site is considered by the investigator to become inaccessible, a second lesion/lesion site shall be selected as a replacement and this shall be used henceforth so long as it is considered accessible. Subsequent injection sites shall be replaced when they are considered inaccessible. - Where no remaining accessible lesions are present and where benefit of IMSA101 therapy is, in the opinion of the investigator, being derived by the patient, continued injections of IMSA101 into the vicinity of an inaccessible lesion or, in the case that a lesion can no longer be radiographically visualized, into the last known location of the non-visible lesion shall be allowed. - Patients will be admitted to the hospital for observation overnight following IT injection with IMSA101 on Day 1 of Cycle 1. Patients will be followed throughout the study for drug tolerability and safety by collection of clinical and laboratory data, including information on adverse events (AEs) using CTCAE v5.0 criteria, serious adverse events (SAEs), DLTs, concomitant medications, vital signs, and electrocardiograms (ECGs). - Patients will be assessed for anti-tumor efficacy based on radiographic assessments and if applicable, photographic tumor assessments, and analysis of Objective Response Rate (ORR), Time to Progression (TTP), and Progression Free Survival (PFS) using RECIST criteria (Appendix 13.2) at screening and the end (≤ 7 days) of even numbered cycles (Cycle 2, Cycle 4, etc.) after the first dosing. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04020185
Study type Interventional
Source ImmuneSensor Therapeutics Inc.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date September 23, 2019
Completion date September 15, 2023

See also
  Status Clinical Trial Phase
Terminated NCT04551885 - FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Phase 1
Active, not recruiting NCT05054348 - First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Enrolling by invitation NCT06088004 - A Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors Phase 1
Recruiting NCT05055609 - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors Phase 1
Withdrawn NCT05071846 - MVX-ONCO-2 in Advanced Solid Tumors Phase 1
Recruiting NCT05607199 - A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics Phase 1
Active, not recruiting NCT04552288 - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Phase 2
Active, not recruiting NCT06026254 - A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial Phase 1
Recruiting NCT06144671 - GT201 Injection For The Treatment Of Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06032845 - Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11) Phase 2
Recruiting NCT05276284 - Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy Phase 1/Phase 2
Recruiting NCT04121442 - Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04221204 - A Monotherapy in Subjects With Advanced Solid Tumors Phase 1
Terminated NCT03992326 - Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors Phase 1
Recruiting NCT05435339 - A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy Phase 1/Phase 2
Recruiting NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Recruiting NCT06075849 - Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent Phase 1
Recruiting NCT04092673 - Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies Phase 1/Phase 2
Active, not recruiting NCT05586321 - Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors Phase 1